Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

14 Jun
Clarke's Analysis of Drugs and Poisons logo
CLARKE’S ANALYSIS OF DRUGS AND POISONS JUNE 2022 UPDATE

This update contains 4 new monographs and 10 major revisions. Additionally, monoisotopic masses have been added to monographs across Clarke’s.

This update includes:
• 4 new NPS monographs
• 10 revised monographs
• 4 minor updates
• Monoisotopic masses added to monographs globally
• Updated indices

14 Jun
British National Formulary for Children logo
BNF for Children June 2022 Update

This update contains 6 significant changes, 3 dose changes, and 2 new monographs.

Significant Changes:
• Ear: updated guidance for the management of acute otitis media.
• Human papillomavirus vaccine: updated guidance in-line with UK Health Security Agency recommendations.
• Immunisation schedule: updated guidance for immunisation against human papillomavirus and influenza.
• Influenza vaccine: updated guidance in-line with UK Health Security Agency recommendations.
• Paediatric Steroid Treatment Card to support early recognition and treatment of adrenal crisis in children with adrenal insufficiency [British Society for Paediatric Endocrinology and Diabetes] (advice in alclometasone dipropionate; beclometasone dipropionate; benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide; betamethasone; budesonide; ciclesonide; cinchocaine hydrochloride with fluocortolone caproate and fluocortolone pivalate; cinchocaine with hydrocortisone; cinchocaine with prednisolone; ciprofloxacin with fluocinolone acetonide; clobetasol propionate; clobetasone butyrate; deflazacort; dexamethasone; diflucortolone valerate; fludrocortisone acetate; fludroxycortide; flumetasone pivalate with clioquinol; fluocinolone acetonide; fluocinonide; fluorometholone; fluticasone; gentamicin with hydrocortisone; hydrocortisone; hydrocortisone butyrate; hydrocortisone with lidocaine; loteprednol etabonate; methylprednisolone; mometasone furoate; prednisolone; triamcinolone acetonide; triamcinolone hexacetonide; see example in  dexamethasone).
• Pain, chronic: new guidance for management in children.

Dose Changes:
• Dexamethasone [update to dosing for COVID-19 requiring supplemental oxygen].
• Erythromycin [amended age range for otitis media and sore throat in children].
• Human papillomavirus vaccines [update to indications and dosing].

New Monographs:
Givlaari® [givosiran].
Rinvoq® [upadacitinib].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

14 Jun
The Green Guide logo
The Green Guide June 2022 Update

The 2022 edition of the Rules and Guidance for Pharmaceutical Distributors 2022 (The Green Guide) is now available through MedicinesComplete. 

This new edition of the MHRA Green Guide has been updated to incorporate new guidance on pharmacovigilance for wholesalers, the naming of sites on a licence, self-inspection, and the responsible person for import.

It brings together in one chapter EU guidance on good distribution practice and the MHRA’s expectations for compliance. There is also a new flowchart for the registration of handling active substances. Comprehensive new content includes:

  • Amended extracts from the Human Medicines Regulations 2012 relating to:
    o wholesale dealing,
    o brokering medicine and
    o importing and distributing active substances.
  • UK guidance on complying with the EU guidelines on Good Distribution Practice for wholesale distributors and brokers of medicines and importers and distributors of active substances,
  • UK guidance on
    o risk-based inspections,
    o conditions of holding a wholesale dealer’s licence, a broker registration, and an active substance registration,
    o a responsible person for import and
    o controls on certain medicinal products.
14 Jun
Orange Guide logo
The Orange Guide June 2022 Update

The 2022 edition of the Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2022 (The Orange Guide) is now available through MedicinesComplete.

The new edition of the MHRA Orange Guide has been updated to incorporate new European and UK guidance, information and UK legislation relating to the manufacture and distribution of human medicines, active substances, and brokering medicines.

Now in its 11th edition, the Orange Guide has been updated to incorporate changes made after the UK’s exit from the European Union on the 31st January 2020.

Comprehensive new content includes:

  • amended extracts from the Human Medicines Regulations 2012 relating to:
    o manufacture, importation and assembly,
    o wholesale dealing,
    o brokering medicine and
    o manufacturing, importing and distributing active substances.
  • The Code of Practice for Qualified Persons in chapter three, Guidance on Manufacture and Importation.
  • UK guidance on complying with the EU guidelines on Good Distribution Practice for wholesale distributors and brokers of medicines and manufacturers, importers and distributors of active substances.
  • UK guidance on:
    o risk-based inspections,
    o conditions of holding a manufacturer’s licence, wholesale dealer’s licence, a broker registration and an active substance registration, and
    o controls on certain medicinal products.

There is also new guidance on:

  • Conditions of holding a manufacturing authorisation for investigational medicinal products,
  • Importing guidance for investigational medicinal products from countries on a list to Great Britain,
  • Pharmaceutical Quality System expectations and Authorisation requirements for investigational medicinal products importation oversight,
  • List of approved countries for import,
  • Pharmacovigilance for wholesalers,
  • The naming of sites on a wholesale dealer’s licence,
  • Self-inspection for wholesale dealers and the responsible person for import.

Plus, revised GMP Annexes 2 and 17, and Commission guidance on principles and guidelines for good manufacturing practice for investigational medicinal products for human use and arrangements for inspections, for medicinal products for human use and for active substances for medicinal products for human use.

14 Jun
British National Formulary logo
British National Formulary June 2022 Update

This update contains 8 significant changes, 3 dose changes, 1 new monograph, and 2 new preparations.

Significant Changes:
• Colecalciferol [maximum daily dose added for treatment of vitamin D deficiency].
• Ear: updated guidance for the management of acute otitis media.
• Ergocalciferol [maximum daily dose added for treatment of vitamin D deficiency].
• Esketamine (Spravato®): new requirement to register patients onto Spravato® Register and Alert system.
• Human papillomavirus vaccine: updated guidance in-line with UK Health Security Agency recommendations.
• Immunisation schedule: updated guidance for immunisation against human papillomavirus and influenza.
• Influenza vaccine: updated guidance in-line with UK Health Security Agency recommendations.
• Pregabalin (Lyrica®): findings of safety study on risks during pregnancy [MHRA/CHM advice].

Dose Changes:
• Erythromycin [amended age range for otitis media and sore throat in children].
• Human papillomavirus vaccines [update to indications and dosing].
• Isavuconazole [addition of dose equivalence and conversion statement].

New Monographs:
Givlaari® [givosiran].

New Preparations:
Xaqua® [metolazone].
Zubsolv® [buprenorphine with naloxone].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

14 Jun
Drug Monitoring Checker June 2022 Update

This update contains 4 new monographs, and 9 minor updates.

New monographs: Acebutolol; Celiprolol hydrochloride; Metoprolol tartrate; Nebivolol

Minor updates: Bendroflumethiazide; Chlortalidone; Dronedarone; Eplerenone; Indapamide; Spironolactone; Atenolol; Bisoprolol fumarate; Propranolol hydrochloride

View more